HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, international biopharmaceutical firm centered on growing differentiated molecules and mixture therapies for sufferers with most cancers, at this time introduced that the Compensation Committee of the Firm’s Board of Administrators granted 4 new workers choices to buy a complete of 66,900 shares of the Firm’s frequent inventory at an train worth per share of $15.96, which was the closing worth on December 23, 2024, and restricted inventory items to accumulate a complete of 33,450 shares of the Firm’s frequent inventory. The fairness awards have been granted pursuant to the Firm’s 2020 Inducement Plan, which was permitted by the Firm’s Board of Administrators in January 2020 pursuant to the inducement exception beneath NYSE Listed Firm Handbook Rule 303A.08.
About Arcus Biosciences (NYSE:)
Arcus Biosciences is a clinical-stage, international biopharmaceutical firm growing differentiated molecules and mixture medicines for individuals with most cancers. In partnership with business collaborators, sufferers and physicians all over the world, Arcus is expediting the event of first- or best-in-class medicines in opposition to well-characterized organic targets and pathways and learning novel, biology-driven combos which have the potential to assist individuals with most cancers dwell longer. Based in 2015, the corporate has expedited the event of a number of investigational medicines into scientific research, together with new mixture approaches that focus on TIGIT, PD-1, HIF-2a, CD73, twin A2a/A2b receptor, CD39 and AXL. For extra details about Arcus Biosciences’ scientific and preclinical applications, please go to www.arcusbio.com.
Inducement PR
Supply: Arcus Biosciences
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20241224871937/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Technique
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Company Communications
(650) 922-1269
hkolkey@arcusbio.com
Supply: Arcus Biosciences
